Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study
- PMID:15126436
- DOI: 10.1001/jama.291.17.2086
Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study
Abstract
Context: The duration of protection from tuberculosis of BCG vaccines is not known.
Objective: To determine the long-term duration of protection of a BCG vaccine that was previously found to be efficacious.
Design: Retrospective record review using Indian Health Service records, tuberculosis registries, death certificates, and supplemental interviews with trial participants.
Setting and participants: Follow-up for the period 1948-1998 among American Indians and Alaska Natives who participated in a placebo-controlled BCG vaccine trial during 1935-1938 and who were still at risk of developing tuberculosis. Data from 1483 participants in the BCG vaccine group and 1309 in the placebo group were analyzed.
Main outcome measures: Efficacy of BCG vaccine, calculated for each 10-year interval using a Cox regression model with time-dependent variables based on tuberculosis events occurring after December 31, 1947 (end of prospective case finding).
Results: The overall incidence of tuberculosis was 66 and 138 cases per 100 000 person-years in the BCG vaccine and placebo groups, respectively, for an estimate of vaccine efficacy of 52% (95% confidence interval, 27%-69%). Adjustments for age at vaccination, tribe, subsequent BCG vaccination, chronic medical illness, isoniazid use, and bacille Calmette-Guérin strain did not substantially affect vaccine efficacy. There was slight but not statistically significant waning of the efficacy of BCG vaccination over time, greater among men than women.
Conclusion: In this trial, BCG vaccine efficacy persisted for 50 to 60 years, suggesting that a single dose of an effective BCG vaccine can have a long duration of protection.
Comment in
- A booster for tuberculosis vaccines.Dye C.Dye C.JAMA. 2004 May 5;291(17):2127-8. doi: 10.1001/jama.291.17.2127.JAMA. 2004.PMID:15126443No abstract available.
Similar articles
- Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial.Usher NT, Chang S, Howard RS, Martinez A, Harrison LH, Santosham M, Aronson NE.Usher NT, et al.JAMA Netw Open. 2019 Sep 4;2(9):e1912014. doi: 10.1001/jamanetworkopen.2019.12014.JAMA Netw Open. 2019.PMID:31553471Free PMC article.
- BCG vaccination among Canadian Indians and Inuit: the epidemiological bases for policy decision.Young TK.Young TK.Can J Public Health. 1985 Mar-Apr;76(2):124-9.Can J Public Health. 1985.PMID:4005772
- Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis.Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, Fine PE, Smith PG, Lipman M, Elliman D, Watson JM, Drumright LN, Whiting PF, Vynnycky E, Rodrigues LC.Abubakar I, et al.Health Technol Assess. 2013 Sep;17(37):1-372, v-vi. doi: 10.3310/hta17370.Health Technol Assess. 2013.PMID:24021245Free PMC article.Review.
- The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV.Colditz GA, et al.Pediatrics. 1995 Jul;96(1 Pt 1):29-35.Pediatrics. 1995.PMID:7596718
- Recent developments in tuberculosis vaccines.Haile M, Källenius G.Haile M, et al.Curr Opin Infect Dis. 2005 Jun;18(3):211-5. doi: 10.1097/01.qco.0000168380.08895.9a.Curr Opin Infect Dis. 2005.PMID:15864097Review.
Cited by
- Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns.Soares AP, Kwong Chung CK, Choice T, Hughes EJ, Jacobs G, van Rensburg EJ, Khomba G, de Kock M, Lerumo L, Makhethe L, Maneli MH, Pienaar B, Smit E, Tena-Coki NG, van Wyk L, Boom WH, Kaplan G, Scriba TJ, Hanekom WA.Soares AP, et al.J Infect Dis. 2013 Apr;207(7):1084-94. doi: 10.1093/infdis/jis941. Epub 2013 Jan 4.J Infect Dis. 2013.PMID:23293360Free PMC article.
- Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial.Usher NT, Chang S, Howard RS, Martinez A, Harrison LH, Santosham M, Aronson NE.Usher NT, et al.JAMA Netw Open. 2019 Sep 4;2(9):e1912014. doi: 10.1001/jamanetworkopen.2019.12014.JAMA Netw Open. 2019.PMID:31553471Free PMC article.
- Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.Wedlock DN, Denis M, Skinner MA, Koach J, de Lisle GW, Vordermeier HM, Hewinson RG, van Drunen Littel-van den Hurk S, Babiuk LA, Hecker R, Buddle BM.Wedlock DN, et al.Infect Immun. 2005 Jun;73(6):3540-6. doi: 10.1128/IAI.73.6.3540-3546.2005.Infect Immun. 2005.PMID:15908383Free PMC article.
- Tuberculosis Vaccine Development: Progress in Clinical Evaluation.Sable SB, Posey JE, Scriba TJ.Sable SB, et al.Clin Microbiol Rev. 2019 Oct 30;33(1):e00100-19. doi: 10.1128/CMR.00100-19. Print 2019 Dec 18.Clin Microbiol Rev. 2019.PMID:31666281Free PMC article.Review.
- Diabetes and tuberculosis, US National Health Interview Survey, 2000-2005.Marks SM.Marks SM.Int J Tuberc Lung Dis. 2011 Jul;15(7):982-4. doi: 10.5588/ijtld.10.0637.Int J Tuberc Lung Dis. 2011.PMID:21682976Free PMC article.
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Medical